324 related articles for article (PubMed ID: 15468060)
1. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
Habel ME; Lemieux R; Jung D
J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
[TBL] [Abstract][Full Text] [Related]
3. c-Myc over-expression in Ramos Burkitt's lymphoma cell line predisposes to iron homeostasis disruption in vitro.
Habel ME; Jung D
Biochem Biophys Res Commun; 2006 Mar; 341(4):1309-16. PubMed ID: 16466700
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
5. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
[TBL] [Abstract][Full Text] [Related]
6. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
7. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
Wolf J; Pawlita M; Bullerdiek J; zur Hausen H
Cancer Res; 1990 May; 50(10):3095-100. PubMed ID: 2159373
[TBL] [Abstract][Full Text] [Related]
8. c-myc Suppression in Burkitt's lymphoma cells.
Simonsson T; Henriksson M
Biochem Biophys Res Commun; 2002 Jan; 290(1):11-5. PubMed ID: 11779125
[TBL] [Abstract][Full Text] [Related]
9. Translocations involving c-myc and c-myc function.
Boxer LM; Dang CV
Oncogene; 2001 Sep; 20(40):5595-610. PubMed ID: 11607812
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Marampon F; Ciccarelli C; Zani BM
Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
[TBL] [Abstract][Full Text] [Related]
11. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
Bemark M; Neuberger MS
Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
[TBL] [Abstract][Full Text] [Related]
12. ECA39 is regulated by c-Myc in human and by a Jun/Fos homolog, Gcn4, in yeast.
Ben-Yosef T; Yanuka O; Benvenisty N
Oncogene; 1996 Nov; 13(9):1859-66. PubMed ID: 8934531
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells.
Fan L; Iyer J; Zhu S; Frick KK; Wada RK; Eskenazi AE; Berg PE; Ikegaki N; Kennett RH; Frantz CN
Cancer Res; 2001 Feb; 61(3):1073-9. PubMed ID: 11221835
[TBL] [Abstract][Full Text] [Related]
14. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
[TBL] [Abstract][Full Text] [Related]
15. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
[TBL] [Abstract][Full Text] [Related]
16. The effect of cyclic-AMP on the regulation of c-myc expression in T lymphoma cells.
Albert DA
J Clin Invest; 1995 Apr; 95(4):1490-6. PubMed ID: 7706453
[TBL] [Abstract][Full Text] [Related]
17. Anticancer activities of curcumin on human Burkitt's lymphoma.
Wu Y; Chen Y; Xu J; Lu L
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):348-52. PubMed ID: 12408761
[TBL] [Abstract][Full Text] [Related]
18. Anti-IgM-induced growth inhibition and apoptosis are independent of ornithine decarboxylase in Ramos cells.
Lin CK; Zou HY; Kaptein JS; Yen CF; Kalunta CI; Nguyen TT; Park E; Lad PM
Exp Cell Res; 1997 Nov; 237(1):231-41. PubMed ID: 9417887
[TBL] [Abstract][Full Text] [Related]
19. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]